Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.55 |
| ▸ | PPARA | Q07869 | 13/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111862 | 0.91 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL4798958 | 0.84 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL4798962 | 0.84 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL4081825 | 0.84 | PPARG (0.53) | PPARGPPARACA12CA1CA2 | |
| SCHEMBL4072795 | 0.82 | PPARG (0.56) | PPARGPPARAMAPTALDH1A1 | |
| SCHEMBL4795714 | 0.81 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL4076821 | 0.80 | PPARA (0.58) | PPARGPPARAMAPTPPARD | |
| SCHEMBL4080386 | 0.80 | PPARA (0.58) | PPARGPPARAMAPTPPARD | |
| SCHEMBL4073436 | 0.80 | PPARG (0.56) | PPARGPPARACA12CA1CA2 | |
| SCHEMBL6832987 | 0.80 | PPARG (0.49) | PPARGPPARACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598293-B2 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7314889-B2 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070142470-A1 | COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LIMITED | 2007-06-21 | — | — | US | disclosed |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, PCSK9 | PPARG 172/4885PPARA 182/4885CA12 4144/4885 |
| US-20070142470-A1 | COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LIPA, PCSK9, GPR119 | PPARG 169/4885PPARA 179/4885CA12 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.